Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. [electronic resource]
Producer: 20050921Description: 1042-7 p. digitalISSN:- 0006-4971
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Apoptosis
- Cell Adhesion
- Coculture Techniques
- Cyclin-Dependent Kinases -- antagonists & inhibitors
- DNA-Binding Proteins -- metabolism
- Down-Regulation -- drug effects
- Drug Synergism
- Humans
- Interleukin-6 -- genetics
- Multiple Myeloma -- drug therapy
- Myeloid Cell Leukemia Sequence 1 Protein
- Neoplasm Proteins -- drug effects
- Proto-Oncogene Proteins c-bcl-2 -- drug effects
- Purines -- pharmacology
- Roscovitine
- STAT3 Transcription Factor
- Stromal Cells -- cytology
- Trans-Activators -- metabolism
- Transcription, Genetic -- drug effects
- Tumor Cells, Cultured
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.